EW stock forecast, quote, news & analysis
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease... Show more
Edwards Lifesciences (EW) Stock Analysis: TAVR Leadership and TMTT Momentum Anchor the Structural Heart Growth Story
Key Takeaways
- Edwards Lifesciences (EW) shares traded near $88, essentially flat over the trailing 30 days, with a modest decline of roughly 0.4%.
- The company is a global leader in structural heart therapies, anchored by its transcatheter aortic valve replacement (TAVR) franchise.
- Second-quarter 2026 revenue rose 13.6% year over year to $1.74 billion, with adjusted EPS of $0.78 beating consensus estimates.
- Transcatheter mitral and tricuspid therapies (TMTT) grew about 47% year over year, reinforcing a fast-growing second platform.
- Management raised its full-year 2026 sales growth guidance to 10% to 11% while reaffirming adjusted EPS guidance of $2.95 to $3.05.
- Key watch items include the U.S. TAVR coverage determination, PROGRESS trial data, and upcoming quarterly results.
Current Market Snapshot
Edwards Lifesciences stock has traded in a narrow band in recent weeks, with the latest available price near $87.92. Over the trailing 30 days, shares were essentially unchanged, easing by roughly 0.4% from a prior close near $88.26. The subdued price action contrasts with the company's underlying operating momentum, suggesting investors have largely priced in the strong first-half results while awaiting fresh catalysts around clinical data, reimbursement policy, and the next earnings report.
Sentiment across the medical-device sector has remained broadly constructive, supported by resilient procedure volumes and an aging patient population. Within structural heart, Edwards holds a commanding position, and its valuation continues to reflect the market's expectation of durable, mid-to-high-single-digit TAVR growth complemented by faster expansion in mitral and tricuspid therapies.
Edwards Lifesciences (EW) Business Overview and Competitive Position
Edwards Lifesciences is a medical-device company focused on structural heart disease, including aortic, mitral, and tricuspid valve conditions. Its portfolio is organized around three product groups: TAVR, anchored by the SAPIEN platform; transcatheter mitral and tricuspid therapies, including PASCAL, EVOQUE, and SAPIEN M3; and surgical structural heart, built on RESILIA tissue technologies such as INSPIRIS, MITRIS, and KONECT. The company completed the sale of its Critical Care business in 2024 to sharpen its focus on structural heart.
Edwards competes with large diversified device makers such as Medtronic (MDT), Abbott (ABT), and Boston Scientific (BSX) across the transcatheter valve space. Its competitive strengths include deep clinical evidence for the SAPIEN platform, a broad portfolio spanning repair and replacement, and a track record of disciplined margin expansion. Investors follow the stock closely for procedural-volume trends, regulatory decisions, and adoption of newer therapies.
Recent Developments Driving EW
Edwards reported second-quarter 2026 results in late July, with total sales of $1.74 billion, up 13.6% year over year, and adjusted EPS of $0.78, up 16.4%. TAVR sales reached $1.26 billion, while TMTT sales climbed to roughly $196 million, up about 47% on continued scaling of EVOQUE and the measured rollout of SAPIEN M3. Surgical sales rose 6.5%, supported by RESILIA adoption and U.S. approval of the ECLIPTIS left atrial appendage system.
On the strength of that performance, Edwards raised its full-year 2026 sales growth guidance to 10% to 11%, lifted its TAVR growth outlook to 8% to 9%, and increased its TMTT sales range to $760 million to $780 million, while reaffirming adjusted EPS guidance. The company has also continued rolling out the updated SAPIEN X4-S platform and remains engaged on a U.S. national coverage determination for TAVR. Its balance sheet remains solid, with roughly $2.9 billion in cash and about $600 million in debt, alongside a meaningful share-repurchase authorization.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that monitor thousands of tickers across the market. Tickeron offers hundreds of automated trading bots, each designed around distinct strategies, timeframes, and performance metrics, but only the top-performing and most relevant bots are featured in this section. The bots vary widely, from short-term pattern recognition to longer-horizon trend-following approaches, giving traders a range of perspectives on stocks like Edwards Lifesciences. Exploring the page can help investors identify AI tools aligned with their own trading style and objectives.
2026 Outlook and What Investors Should Watch
For the balance of 2026, investors are likely to focus on several catalysts. The final U.S. Medicare national coverage determination for TAVR could shape the pace of adoption in the largest single market, while the PROGRESS trial in moderate aortic stenosis, with results expected at the TCT conference, may inform the long-term addressable market. Continued scaling of TMTT therapies, including EVOQUE and SAPIEN M3, and the surgical rollout of ECLIPTIS and TRIFORMIS, are additional growth drivers to monitor.
Macroeconomic factors, foreign-exchange effects, and tax-policy changes—including California's new limitation on R&D credits—remain relevant to margins and earnings. Competitive launches across the transcatheter valve landscape also bear watching. As always, these factors are forward-looking considerations rather than predictions, and outcomes will depend on clinical, regulatory, and market developments as they unfold.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EW's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EW turned positive on October 14, 2026. Looking at past instances where EW's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on EW as a result. In 56 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
EW moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in 170 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
The Aroon Indicator for EW entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 32 (best 1 - 100 worst), indicating outstanding price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.799) is normal, around the industry mean (2.923). P/E Ratio (50.805) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.852) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (7.974) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalNursingServices